A randomized phase 3 study of maintenance therapy with S‐1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus S‐1 for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L)
- 2 June 2020
- Vol. 126 (16), 3648-3656
- https://doi.org/10.1002/cncr.32987
Abstract
Background A randomized phase 3 study was performed to investigate the efficacy and safety of maintenance therapy with S‐1 after induction therapy with carboplatin plus S‐1 in patients with advanced squamous non–small cell lung cancer (NSCLC). Methods Chemotherapy‐naive patients with advanced or relapsed squamous NSCLC were treated with carboplatin (area under the curve of 5 on day 1 every 3 weeks) plus S‐1 (40 mg/m2 twice per day on days 1‐14 every 3 weeks) as induction therapy. Patients who did not progress after 4 cycles of induction therapy were randomized to receive either S‐1 plus best supportive care (BSC) or BSC alone. The primary objective of the study was to confirm the superiority of S‐1 plus BSC in comparison with BSC alone with respect to progression‐free survival. Results Of the 365 patients enrolled in the study, 347 participated in the induction phase, and 131 of these individuals were randomized to receive S‐1 plus BSC (n = 67) or BSC alone (n = 64). The risk of disease progression was significantly lower for patients in the S‐1 plus BSC arm than those in the BSC‐alone arm (hazard ratio, 0.548; 95% confidence interval, 0.374‐0.802; P = .0019). The most common toxicities during maintenance therapy with S‐1 included anorexia, anemia, and fatigue, but most cases were not severe. Conclusions Continued maintenance with S‐1 plus BSC is an effective and well‐tolerated treatment option for patients with advanced squamous NSCLC previously treated with carboplatin plus S‐1.Keywords
Funding Information
- Taiho Pharmaceutical
This publication has 15 references indexed in Scilit:
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2016
- Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2016
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Lung Cancer Incidence Trends by Gender, Race and Histology in the United States, 1973–2010PLOS ONE, 2015
- Global cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2015
- Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS studyAnnals of Oncology, 2012
- Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer: Results of a West Japan Oncology Group StudyJournal of Clinical Oncology, 2010
- Japanese Lung Cancer Registry Study: First Prospective Enrollment of a Large Number of Surgical and Nonsurgical Cases in 2002Journal of Thoracic Oncology, 2010
- Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish populationMutation research. Reviews in mutation research, 2006
- What is a clinically meaningful change on the Functional Assessment of Cancer Therapy–Lung (FACT-L) Questionnaire?: Results from Eastern Cooperative Oncology Group (ECOG) Study 5592Journal of Clinical Epidemiology, 2002